Quintiles going private
Quintiles accepts bid from Chairman Dennis Gillings, PhD, to buy company for $14.50/share. Agreement represents $3.25/share increase over Gillings' original proposal (1"The Pink Sheet" Nov. 18, 2002, p. 9)...
You may also be interested in...
Quintiles will look for potential buyers after rejecting an acquisition offer from founder and Chairman Dennis Gillings, PhD
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.